Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Veracyte (VCYT)
NASDAQ:VCYT
VCYT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.61 - $47.32
Previous CloseN/A
Volume253.49K
Average Volume (3M)813.33K
Market Cap
$3.13B
Enterprise Value$2.42B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Feb 24, 2025EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding77,499,626
10 Day Avg. Volume774,596
30 Day Avg. Volume813,333
Standard Deviation0.16
R-Squared0.30
Alpha0.00093
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.36
Price to Cash Flow (P/CF)26.10
P/FCF Ratio28.30
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.74
Enterprise Value/Ebitda180.08
Forecast
1Y Price Target
$51.00Price Target Upside24.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Product DevelopmentVCYT has a rich pipeline including international kitted tests, minimal residual disease (MRD) test, and Percepta Nasal Swab test.
Revenue PerformanceVCYT reported revenue above expectations, driven by continued strength in their testing business.
Bears Say
Stock ValuationRecent stock price increase suggests that current momentum is already reflected in the stock value, while significant benefits from new initiatives will take time to materialize.
---
Ownership Overview
1.22% Insiders
33.48% Mutual Funds
31.50% Other Institutional Investors
8.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VCYT FAQ
What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was $18.61 and its highest was $47.32 in the past 12 months.
What is Veracyte’s market cap?
Veracyte’s market cap is $3.13B.
When is Veracyte’s upcoming earnings report date?
Veracyte’s upcoming earnings report date is Feb 24, 2025 which is in 2 days.
How were Veracyte’s earnings last quarter?
Veracyte released its earnings results on Nov 06, 2024. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.032 by $0.158.
Is Veracyte overvalued?
According to Wall Street analysts Veracyte’s price is currently Undervalued.
Does Veracyte pay dividends?
Veracyte does not currently pay dividends.
What is Veracyte’s EPS estimate?
Veracyte’s EPS estimate is 0.11.
How many shares outstanding does Veracyte have?
Veracyte has 77,499,626 shares outstanding.
What happened to Veracyte’s price movement after its last earnings report?
Veracyte reported an EPS of $0.19 in its last earnings report, beating expectations of $0.032. Following the earnings report the stock price went up 2.05%.
Which hedge fund is a major shareholder of Veracyte?
Currently, no hedge funds are holding shares in VCYT
---
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.00 (24.24% Upside)
$51.00 (24.24% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 748.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $305.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.21%
12-Months-Change
Fundamentals
Return on Equity
-0.83%
Trailing 12-Months
Asset Growth
13.34%
Trailing 12-Months
Company Description
Veracyte
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
---
VCYT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong positive sentiment driven by record revenue growth, robust performance in the Decipher and Afirma segments, and an improved financial outlook. Despite some challenges in the product segment and the decision to pause the Envisia CLIA test, the positive aspects significantly outweighed the negatives.Read More>---
VCYT Stock 12 Month Forecast
Average Price Target
$51.00
▲(24.24% Upside)
Technical Analysis
Best Analysts Covering VCYT
1 Year
1 Year Success Rate
16/21 ratings generated profit
1 Year Average Return
+53.96%
reiterated a buy rating 4 months ago
Copying Sung Ji Nam's trades and holding each position for 1 Year would result in 76.19% of your transactions generating a profit, with an average return of +53.96% per trade.
---